{"name":"Janssen Pharmaceutica N.V., Belgium","slug":"janssen-pharmaceutica-nv-belgium","ticker":"","exchange":"","domain":"janssenpharmaceuticanvbelgium.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"JNJ-64042056","genericName":"JNJ-64042056","slug":"jnj-64042056","indication":"Other","status":"phase_2"},{"name":"early initiation of treatment with Risperdal Consta","genericName":"early initiation of treatment with Risperdal Consta","slug":"early-initiation-of-treatment-with-risperdal-consta","indication":"Other","status":"marketed"},{"name":"routine initiation of treatment with Risperdal Consta","genericName":"routine initiation of treatment with Risperdal Consta","slug":"routine-initiation-of-treatment-with-risperdal-consta","indication":"Other","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Risperidone Long acting injectable","genericName":"Risperidone Long acting injectable","slug":"risperidone-long-acting-injectable","indication":"Schizophrenia","status":"marketed"}]}],"pipeline":[{"name":"JNJ-64042056","genericName":"JNJ-64042056","slug":"jnj-64042056","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Risperidone Long acting injectable","genericName":"Risperidone Long acting injectable","slug":"risperidone-long-acting-injectable","phase":"marketed","mechanism":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia","Bipolar I disorder (maintenance treatment)","Irritability associated with autism spectrum disorder","Aggression and behavioral disturbances in patients with psychotic disorders"],"catalyst":""},{"name":"early initiation of treatment with Risperdal Consta","genericName":"early initiation of treatment with Risperdal Consta","slug":"early-initiation-of-treatment-with-risperdal-consta","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"routine initiation of treatment with Risperdal Consta","genericName":"routine initiation of treatment with Risperdal Consta","slug":"routine-initiation-of-treatment-with-risperdal-consta","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":1,"marketed":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}